Press Releases

Date Title  
Toggle Summary Natera Prices $250 Million Convertible Senior Notes Due 2027
SAN CARLOS, Calif. , April 13, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that it has priced $250 million aggregate principal amount of convertible senior notes due 2027 (the "notes"). The notes will be sold to qualified institutional buyers pursuant to Rule 144A under the
Toggle Summary Natera to Offer $250 Million Convertible Senior Notes Due 2027
SAN CARLOS, Calif. , April 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA) today announced that it proposes to offer $250 million aggregate principal amount of convertible senior notes due 2027 (the "notes"), subject to market conditions and other factors.
Toggle Summary Natera Announces Preliminary First Quarter 2020 Financial Results
Quarterly unit growth largest in company history SAN CARLOS, Calif. , April 13, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced preliminary operational and financial results for the quarter ended March 31, 2020 . Natera
Toggle Summary Coverage for Natera's Panorama® Prenatal Test Extended by Greater Than 20 Million Lives
SAN CARLOS, Calif. , April 6, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing and non-invasive prenatal testing (NIPT) today announced an expansion in coverage of its Panorama test to all pregnant women, regardless of age, after a major
Toggle Summary New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer
Breakthrough blood test detects relapse earlier and helps patients avoid unnecessary clinic visits with GI Expanded Access Program SAN CARLOS, Calif. , April 2, 2020 /PRNewswire/ -- A new, peer-reviewed case study published in JCO Precision Oncology 1 demonstrates the unique ability of Signatera
Toggle Summary Natera Provides Remote Access to Tests Without Requiring Live Office Visits
Enabling continuity of care while allowing patients to stay home SAN CARLOS, Calif. , March 19, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced expanded access to its virtual ordering platforms and remote testing capabilities
Toggle Summary Natera to Showcase Leadership in Cell-Free DNA at CEoT Conference
SAN CARLOS, Calif. , March 4, 2020 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will be participating in the Cutting Edge of Transplantation (CEoT) conference taking place March 5-7, 2020 in Phoenix, Arizona .
Toggle Summary Natera to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will webcast live presentations at the Cowen and Company 40 th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 8:20
Toggle Summary Natera Receives Favorable Medicare Reimbursement Pricing for Prospera™
SAN CARLOS, Calif. , March 3, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that its Prospera donor-derived cell-free DNA (dd-cfDNA) test has been priced favorably at $2,840.75 .
Toggle Summary Natera Reports Fourth Quarter and Year 2019 Financial Results
SAN CARLOS, Calif. , Feb. 26, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and the year ended December 31, 2019 and provided an update on recent

Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.